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Beta-adrenergic blocking agents are commonly used in
combination with digitalis to control excessive heart rate
during exercise in patients with chronic atrial fibrilla-
tion. However, little is known about the effect of beta-
adrenergic blockade on exercise capacity in these pa-
tients. Accordingly, a randomized, double-blind, cross-
over placebo-controlled study was performed to assess
the efficacy of celiprolol, a new cardioselective beta-
blocker with partial intrinsic sympathomimetic activity,
on exercise performance in nine men with chronic atrial
fibrillation. All but one patient was receiving mainte-
nance digitalis during the study. Heart rate, blood pres-
sure and gas exchange variables were measured at rest
and during treadmill exercise testing while the patients
were receiving maintenance celiprolol or placebo.
Significant reductions in heart rate and systolic blood
pressure compared with control values were observed
at submaximal exercise, at the gas exchange anaerobic
In patients with chronic atrial fibrillation, the primary goal
of therapy is to control the rapid heart rate response at rest
and during exercise. Historically, digoxin has been the drug
of choice to control rest heart rate in atrial fibrillation (1,2).
However, digoxin has limited effectiveness in controlling
heart rate during exercise or other stress (3-5) . Recently,
the concomitant use of beta-adrenergic or calcium channel
blocking agents with digoxin has been recommended as a
better means of controlling heart rate in atrial fibrillation
(6-12) .
A concern with beta-adrenergic blockade therapy is the
possible reduction in cardiac output resulting not only from
a reduction in maximal heart rate , but also from the depres-
sion of myocardial function. If cardiac output is significantly
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threshold and at maximal exertion while the patients
were taking celiprolol. However, oxygen uptake at the
gas exchange anaerobic threshold during celiprolol ther-
apy was 12.3 versus 14.0 ml oxygen/kg per min during
placebo administration (a 12% difference, p < 0.01).
Similarly, oxygen uptake at maximal exertion during
celiprolol therapy was 17.6 versus 21.0 ml/kg per min
during placebo administration (a 16% difference, p <
0.01). Treadmill time was also reduced during the eel-
iprolol phase compared with placebo (l1.3 versus 10.3
minutes; a 19% difference, p < 0.01).
These results indicate that in patients with atrial fi-
brillation the major beneficialeffects of beta-adrenergic
blockade-reduced submaxirnal and maximal exercise
heart rate and blood pressure-must be weighedagainst
the decrease in exercise capacity.
(J Am Coil CardioI1987;10:314-20)
reduced, maximal oxygen uptake would be decreased, caus-
ing a reduction in exercise capacity (13,14). Studies in nor-
mal subjects (15-21) have provided conflicting results on
the effect of beta-adrenergic blocking agents on maximal
oxygen uptake and other ventilatory variables associated
with aerobic capacity . Similarly, in studies of patients with
atrial fibrillation (7-10), the effect of beta-adrenergic block-
ade on maximal exercise capacity has been inconclusive,
and no study included measurements of ventilatory vari-
ables .
The purpose of the present study was to investigate the
effect of maximal dose (600 mg) celiprolol, a beta-I selec-
tive adrenergic blocker, on hemodynamic and respiratory
gas exchange variables during maximal exercise testing in
patients with chronic atrial fibrillation.
Methods
Study patients. Nine male volunteers, ranging in age
from 58 to 69 years, with chronic atrial fibrillation of at
0735-1097/87 /$3.50
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Patient No. Age (yr) Duration or AI' (y r) Medication
I 58 10 Digoxin, 0.25 rng
2 64 12 Digoxin. 0.25 mg
3 60 I Digoxin. 0.25 rng
4 69 3 Digoxin. 0 .125 rng
5 66 15 Quinidine gluconaie,
324 mg TID
6 60 10 Digoxin. 0. 375 mg
7 64 6 Digoxin. 0 .25 rng
8 63 10 to [5 Digoxin. 0 .25 mg
9 68 > 3 Digoxin. 0 .25 mg:
quinidine gluconate,
324 rug TID
Clinical Diagnosis
Lone AI'
Lone AI'
Lone AI'
Mitral valve
replacement. CABG
Lone AI'
Mitral valve replacement
Mitral regurgitation
Mitral regurgitation
Lone AI'
AI' =' atrial fibrillation; CABS =' coronary artery bypass grafting; TID =' three times/day.
Figure I. Treatment and exercise protocol design.
tests were continued to volitional fatigue or dyspnea, or
both. No exercise test was limited by angina pectoris.
Pulmonary gas exchange variables were determined con-
tinuously throughout the exercise test using the Beckman
Horizon MMC exercise testing system. The precision and
reproducibility of this system has been validated by Jones
(25). The reproducibility of the exercise system employed
in the present study was documented using techniques out-
lined by Jones and Campbell (26).
A standard 12 lead electrocardiogram (ECG) and blood
pressure were obtained at rest and throughout the exercise
test and recovery period. The number of ECG complexes
multiplied by a factor of 10 in a 6 second rhythm strip at
the end of each minute was used to determine heart rate.
Blood pressure was determined using a clinical sphygmo-
manometer at rest, during the last minute of each stage of
exercise, at maximal effort and during recovery.
Points of analysis . Analysis of hemodynamic and pul-
monary gas exchange variables was performed at a sub-
maximalwork load (3.0 mph/O% grade), at the gas exchange
anaerobic threshold and at maximal exertion. Pulmonary
gas exchange variables include oxygen uptake (V0 2 , mllkg
per min standard temperature and pressure, dry ISTPDj);
carbon dioxide production (VC0 2 , liters/min STPD); minute
ventilation (VE, liters/min body temperature and pressure.
least 6 months' duration were included in the study. Clinical
features and medications are listed in Table I. All patients
but one were receiving digoxin therapy. None had conges-
tive heart failure at the time of the study and all were in
New York Heart Association functional class I or II. All
rights and privileges were honored in accordance with an
established human subjects protocol and informed consent
was obtained as approved by the Human Subjects Com-
mittee at the Long Beach Veterans Administration Hospital.
All patients had left atrial enlargement with normal left
ventricular function as interpreted by M-mode and two-
dimensional echocardiography before entering the study.
Routine pulmonary function tests were performed during
each treatment.
Study design. Each patient participated in a 3 week
randomized double-blind placebo-controlled protocol with
a I week washout period between treatments. Exercise tests
were performed between 2 and 3 hours after administration
of the medication on the fifth to seventh day of therapy(Fig.
I) . The active medication utilized in the present study, eel-
iprolol, is a hydrophilic cardioselective beta-adrenergic
blocker with partial intrinsic sympathomimetic activity and
a plasma half-life of 5 to 6 hours, with peak levels occurring
at 2 to 4 hours (22). A 600 mg dose of celiproJol. the
maximal dose used in preliminary human studies, was cho-
sen for optimal heart rate contro!' This dose was well tol-
erated by all patients.
Testing procedures. Patients were exercised on a cal-
ibratedmotor-driven treadmill and instructed to abstain from
food, coffee and cigarettes for at least 3 hours before testing.
From two previous treadmill tests, individualized protocols
were designed for each patient such that the maximal ex-
ercise test lasted between 10 and 12 minutes. These pro-
tocols conformed to guidelines for optimizing cardiopul-
monary assessment as outlined by Buchfuhrer et al. (23).
The patient's subjective perception of exertion was evalu-
ated using the Borg 6 to 20 point scale (24). All exercise
Placebo
Celiprolol
Week 1
e.ercise Test
at 5-7 days
Placebo
Celiprolol
Week 3
ExerCise Test
at 5-7 days
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Standing rest
Placebo
Celiprolol
Mean diffe rence
3 mphlO% grade
Placebo
Cel iprolol
Mean difference
Gas exchange
anaerobic threshold
Placebo
Celiprolol
Mean difference
Maximal exertion
Placebo
Celipro lol
Mean difference
Heart Rate
(beats/min)
91 ± 17
77 ± 15
- 14*
123 ± 22
105 ± 12
- 18*
147 ± 28
102 ± 14
- 45t
171 ± 30
118 ± 20
- 53t
Blood Pressure (mm Hg)
Systolic Diastolic
131 ± 16 80 ± 6
127 ± 14 79 ± 6
- 4 - I
152 ± 28 79 ± 7
133 ± 18 76 ± 7
- 19* - 3
163 ± 24 8 1 ± 8
133 ± 18 76 ± 5
- 30t - 5
176 ± 34 79 ± 4
137 ± 26 73 ± 6
-39t - 6*
*p < 0 .05 between celiprolol and placebo; t p < 0.0 1 between celiprolol and placebo.
saturated [BTPS)); oxygen pulse (oxygen uptake [rnl/min]
divided by heart rate) which is proportional to the arterio-
venous oxygen content difference multiplied by stroke vol-
ume; and respiratory exchange ratio ([RER] = vco, di-
vided by VOz). The gas exchange anaerobic threshold (the
beginning of a systematic increase in VE/VOz without a
concomitant increase in VE/VeOz) was determined by two
independent blinded observers as outlined by Sullivan et al.
(27) . All result s were entered into a Lotus 1-2-3 spreadsheet.
analyzed by a paired Student 's t test from Minitab and
presented as mean values ± SO .
Results
Heart rate , blood pressure and pulmonary gas exchange
variables observed at rest, submaximal exercise (3.0 mphlO%
Table 3. Pulmonary Gas Exchange Results in Nine Patients
grade), gas exchange anaerobic threshold and max imal ex-
ertion are presented in Tables 2 and 3.
Rest data (Table 2). Standing heart rate was signifi-
cantly reduced during celiprolol therapy . However, there
were no statistically significant differences between celi-
prolol and placebo for rest systolic or diastol ic blood pres-
sure. Rout ine pulmon ary funct ion tests revealed no signif-
icant difference between celiprolol and placebo for forced
vital capacity: 4 .03 ± 0.57 liters (placebo) versus 3.98 ±
0.59 liters (celiprolol) or forced expiratory volume in I
seco nd: 2.86 ± 0 .55 liters/s (placebo) versus 2.82 ± 0 .57
liters/s (celiprolol) .
Progressive exercise (Fig. 2 to 4). Heart rate remained
significantl y reduced throughout exerci se when the patient s
were taking celipro lol, with the difference becoming pro-
Ventilation BTPS Oxygen Uptake STPD RER Oxygen Pulse Perceived
(liters/min) (rnl/kg-rnin) (CO!/vO!) (ml/bea t) Exertion
3 mph/O% grade
Placebo 29.5 ± 5.5 11.9 ± 1.2 0 .80 ± 0.6 8.9 ± 2.5 II ± 2
Celiprolol 30.2 ± 6.9 12.0 ± 1.1 0.80 ± 0.07 10.4 ± 2.7 II ± 1
Mean differe nce + 0 .5 +0 . 1 0 + I.5 t 0
Gas exchange
anaerobic threshold
Placebo 35 . 1 ± 6.8 14.0 ± 1.5 0 .84 ± 0.06 8.9 ± 2.8 13±
Celiprolol 30.5 :!: 5.2 12.3 ± 1.0 0.8 1 ± 0.07 11.0 :!: 2.6 13 :!:
Mean difference - 4 .6t - 1.7t - 0 .03 + 2. l t 0
Maximal exertion
Placebo 72.6 ± 5.2 21.0 ± 2.8 l.11 ± 0.10 11.4 ± 3.3 20 ±
Ce liprolol 66 .5 ± 8. 1 17.6 ± 1.6 l. 1O ± 0.06 13.5 ± 2.6 20 ±
Mean difference -6. 1* 3.4+ -0.01 + 2. 1* 0
*p < 0 .05 between celiprolol and placebo; t p < 0.0 1 between celiprolol and placebo . BTPS = body temperature and pressure , saturated; CO 2 =
carbon diox ide; RER = respiratory exchange ratio; STPD = standard temperature and pressure, dry; V02 = oxygen uptake .
lACC Vol. 10. No.2
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Figure 4. Mean values for ventilation (VE) and oxygen uptake
(VO!) at I minute intervals duringexercise testing. duringplacebo
(e) versus celiprolol (0) therapy. ATGE = gas exchange anaer-
obicthreshold: BTPS = body temperature and pressure. saturated;
STPD = standard temperature and pressure. dry.
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Figure 2. Mean ( ± SEM) heart rate at I minute intervals during
placebo (e) versus celiprolol (0) therapy.
gressively more pronounced with each stage of exercise
(Fig. 2) . In addition, the rate of rise in heart rate was mark-
edly less steep in patients taking celiprolol than in those
taking placebo. Systolic blood pressure was significantly
reduced at each stage of exercise during celiprolol therapy:
Figure 3. Mean ( ± SEM ) systolic blood pressure at the end of
four stages of exercise during placebo (e) versus celiprolol (Ol
therapy.
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a flat response Was observed as a mean increase of only 10
mm Hg occurred from rest throughout all exercise stages
(Fig. 3). Figure 4 plots the mean values for oxygen uptake
and ventilation for each minute during exercise. These val-
ues remained similar until the gas exchange anaerobic
threshold was reached, at which time progressive reductions
in oxygen uptake were observed.
Submaximal exercise (3.0 mph /O % grade) (Tables 2
and 3). Significant reductions in heart rate and systolic
blood pressure (mean decrease 18 beats/min and 19 mm
Hg, respectively) occurred at 3.0 mph/O% grade during
celiprolol therapy (Table 2). There were no statistically sig-
nificant differences between the two treatments in any of
the gas exchange variables at this point, except for an in-
crease in oxygen pulse due to the decrease in heart rate
(Table 3). Although hemodynamic variables were reduced
and oxygen pulse rose during celiprolol therapy. there were
no changes in oxygen uptake or perceived level of exertion
at this moderate work load.
Gas exchange anaerobic threshold (Tables 2 and 3,
Fig. 5). Hemodynamic changes during celiprolol were more
pronounced at this point. with mean decreases in heart rate
and systolic blood pressure of 45 beats/min and 30 mm Hg,
respectively (Table 2). In addition. significant reductions in
oxygen uptake and minute ventilation were observed during
celiprolol therapy (Table 3). Figure 5 graphically illustrates
the reduction in mean oxygen uptake at the gas exchange
anaerobic threshold: oxygen uptake was reduced in eight of
the nine subjects after administration of celiprolol. Oxygen
pulse remained significantly elevated, whereas perceived
exertion and respiratory exchange ratio remained un-
changed.
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Figure5. Oxygen uptake (VO!) values for each subject at the gas
exchange anaerobic threshold during placebo versus celiprolol
therapy. STPD = standard temperature and pressure. dry.
Figure 6. Oxygen uptake (VO!) values at maximal exercise for
each subject during placebo versus celiprolol therapy. STPD
standard temperature and pressure. dry.
15
Figure7. Total treadmill time for each subject while on placebo
versus celiprolol therapy.
pressure at submaximal exercise. at the gas exchange an-
aerobic threshold and at maximal exertion, beta-blockade
impairs maximal exercise capacity in patients with chronic
atrial fi brillation and normal ventricular function. We ob-
served a 16% reduction of measured oxygen uptake at max-
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Maximal exertion (Table 2, Fig. 6 and 7). The mean
respiratory exchange ratio (I. I) and the mean value for
maximal perceived exertion (20) during both phases of ther-
apy document that maximal exertion was attained. During
celiprolol therapy. heart rate and blood pressure were re-
duced (Table 2). Figure 6 demonstrates a signifi cant reduc-
tion in maximal oxygen uptake for each subject and a mean
reduction of 16% during celiprolol therapy. Figure 7 dem-
onstrates a reduction in treadmill time for each individual
and a group decrease of 19%. Also, during celiprolol ther-
apy. there was a significant decrease in maximal minute
ventilation and an increase in oxygen pulse.
Discussion
Determining oxygen uptake from respiratory gas ex-
change analysis during exercise testing allows for the ob-
jective quantitation of both energy production and work
capacity (26.28). In clinical practice. maximal oxygen up-
take is usually estimated from treadmill time or work load
(29.30). This is fraught with many errors because of dif-
ferences in habituation, efficiency and fitness level, all of
which affect the relation of oxygen uptake to treadmill time
or work load (31-36) . To our knowledge, the present study
is the fi rst to directly measure oxygen uptake during exercise
in patients with chronic atrial fibrillation receiving beta-
blocker drug treatment or placebo.
Maximal exertion. The major finding of the present
study is that, despite lowering heart rate and systolic blood
JACC Vol. 10, No. 2
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imal exertion and a 19% reduction in treadmill time during
beta-blockade therapy compared with placebo. Addition-
ally, oxygen uptake was significantly reduced at the gas
exchange anaerobic threshold while the patients were on
beta-blockade therapy relative to placebo.
Few studies in patients with atrial fibrillation have ad-
dressed the effect of beta-adrenergic blockade on maximal
exertion. Although two studies (8,9) have demonstrated ad-
equate heart rate control after beta-adrenergic blockade, one
(8) reported a reduced and the other (9) an increased exercise
capacity. Neither study measured oxygen uptake.
The effect of beta-blockade on maximal oxygen uptake
among subjects with normal sinus rhythm has also been
controversial. Botha decrease (13,14,17,18,20) and no change
(15,19,21) in maximal oxygen uptake have been reported.
Wilmore et al. (19) list several possible causes for this
inconsistency, includingthe type of beta-adrenergic blocker.
method of medication administration, timing of the test with
respect to peak medication effect, length of time on med-
ication, dosage level, exercise protocol. motivation and age
of subject, and statistical analysis used,
The mechanism fo r the reduction in oxygen uptake in our
patients with chronic atrial fibrill ation during beta-blockade
therapy is speculative. Studies indicate that increases in
stroke volume occur until levels of 40 to 60% of maximal
exercise capacity are attained, although at higher levels of
exercise, heart rate becomes the primary factor in cardiac
output. Not only does beta-adrenergic blockade blunt the
heart rate response, but also its negative inotropic effect
may attenuate stroke volume, thereby reducing exercise ca-
pacity,
The increase in oxygen pulse suggests that during beta-
blockade, the patient with atrial fibrill ation is able to com-
pensate for a decreased heart rate by increasing stroke vol-
ume or peripheral oxygen extraction, or both, to meet the
energy requirements of work loads below the gas exchange
anaerobic threshold. Invasive studies in normal subjects given
propranolol suggest that submaximal oxygen uptake is main-
tained by an increased arteriovenous oxygen difference rather
than by an increased stroke volume ( 13,14). The capacity
for stroke volume to increase to maintain cardiac output is
presumably limited by the negative inotropic properties of
beta-adrenergic blockade; thus, the increase in oxygen pulse
we observed may be more likely to reflect increased pe-
ripheral oxygen extraction than increased stroke volume.
Rest and submaximal exercise . The observed reduc-
tions in heart rate at rest and heart rate and systolic blood
pressure submaximally are consistent with other data in
patients with chronic atrial fi brillation and subjects with
normal sinus rhythm (6- 10, 15.19). Celiprolol did not alter
gas exchange variables such as minute ventilation, oxygen
uptake and respiratory exchange ratio. a find ing consistent
with studies among normal subjects (13,15-19). Perceived
exertion was unchanged during the celiprolol phase at 3
mph/O% grade. Thus, beta-adrenergic blockade is effective
for controlling the characteristic rapid heart rate response
to exercise in these patients without altering subjective levels
of exertion or objective gas exchange variables at work loads
below the gas exchange anaerobic threshold.
Gas exchange anaerobic threshold. The true physio-
logic mechanism for the abrupt increase in ventilation with
respect to oxygen uptake at the anaerobic threshold is un-
certain and several current arguments regarding the concept
have recently been published (37- 44). Nevertheless, the gas
exchange anaerobic threshold is an acceptable and repro-
ducible index of the capacity to tolerate submaximal work.
In fact, it has been reported to be a superior index for the
measurement of endurance performance in both normal sub-
jects and patients with coronary artery disease (27,44-46) ,
In our study, a significant decrease in heart rate and
systolic blood pressure occurred at the gas exchange an-
aerobic threshold during celiprolol therapy. The observed
reduction in oxygen uptake at this threshold during beta-
blockade is consistent with data from one study ( 17), but
not from others ( 15, 16). The observation that perceived
exertion did not change between treatments at this point is
an interesting finding. Although patients perceived the work
to be equal, measured oxygen uptake was reduced after beta-
blockade therapy,
Clinical implications. Using a beta-blocker for heart
rate control in patients with chronic atrial fibrillation would
appear appropriate when the goal is to reduce myocardial
oxygen demand. as in patients with angina pectoris. How-
ever, there is the risk of compromising ventilatory oxygen
uptake because of the negative chronotropic and inotropic
effects of beta-adrenergic blockade. Although we cannot be
certain what the effects of a lower dose of celiprolol, that
is. less negative chronotropic and inotropic activity, may
have had on oxygen uptake, studies in normal subjects have
also demonstrated reduced maximal oxygen uptake during
moderate doses of beta-adrenergic blockade. Perhaps cal-
cium channel blockers with dromotropic control but less
negative inotropic effects will prove more advantageous.
Clinically. the decrease in the gas exchange anaerobic
threshold and reduction in oxygen uptake at higher work
loads become important in patients who desire an active
life-style. Because patients perceive an equivalent amount
of work as being harder during beta-adrenergic blockade,
their motivation to engage in previous activities may be
affected. Our results suggest that the effect of beta-adre-
nergic blockers in patients with atrial fibrillation is twofold;
the effective control of submaximal exercise heart rate must
be weighed against the impairment in oxygen delivery at
moderate to heavy work loads. The key to therapy in patients
with atrial fibrillation would appear to be normalizing the
heart rate response to exercise without affecting the gas
exchange anaerobic threshold or maximal oxygen uptake.
We gratefully acknowledge the secretar ial assistance of Lesley Sanderson
and Mona Risch in the preparation of this manuscript.
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